We enable longer and healthier living through detection and monitoring of serious disease

At Chembio, our mission is to be a leader in the development, manufacture and commercialization of diagnostic solutions. We are dedicated to delivering exceptional products that provide ease of use, and rapid and accurate results at the point-of-care (POC). As a global company, we are committed to innovation and the highest quality standards.

At the core of our commitment is our patented Next Generation DPP® (Dual Path Platform) technology. Our DPP® technology is a breakthrough in POC diagnostics, offering significant advantages over lateral-flow technologies including:

Significantly improved sensitivity

Multiplexing – multiple test results via a single blood sample (e.g., HIV-Syphilis Assay)

Application in a number of indications

Today our DPP® technology is the basis of multiple collaborations with healthcare innovators and leaders worldwide spanning infectious diseases such as HIV, Zika, Ebola, syphilis, malaria and febrile illness, as well as potential new uses in the diagnosis of a specific form of cancer and brain injury (concussion).

Medford, US
Size (employees)
131 (est)-15%
Chembio was founded in 1986 and is headquartered in Medford, US

Chembio Office Locations

Chembio has office in Medford
Medford, US

Chembio Metrics

Chembio Summary

Market capitalization

$67.6 m

Closing share price

Chembio's current market capitalization is $67.6 m.

Chembio Financials

Chembio's revenue is $29.5 m in FY, 2013 which is a 6.9% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$29.5 m$27.6 m$24.3 m$17.9 m

Revenue growth, %


Net Income

$530.8 k($1.1 m)($2.4 m)($13.3 m)

Chembio Market Value History

Chembio Online Presence

Chembio Company Life

You may also be interested in